Innovative Medicines Initiative 2 funding opportunities
January 2019

The Innovative Medicines Initiative (IMI) has now launched its 17th Calls for proposals under IMI2. The Call gives researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future.

Why apply?

- Obtain research funding
- Take part in scientifically excellent, patient-centric research
- Join unique consortia involving top teams from industry, academia, SMEs, regulators, and others
- Benefit from the expertise, databases, and infrastructures of consortium partners
- Boost the visibility and status of your organisation in Europe and globally and gain access to new markets

IMI2 – Call 17

IMI2 – Call 17 was launched on 22 January 2019 and is a standard, two-stage Call for proposals. It includes the following topics:

- Optimising future obesity treatment
- Open access chemogenomics library and chemical probes for the druggable genome
- Intelligent prediction and identification of environmental risks posed by human medicinal products

How to apply

- The rules and details of how to apply can be found via the Call pages of the IMI website.
- Follow IMI’s tips for applicants – see bit.ly/IMItips
- Get advice on finding project partners on our partner search page – bit.ly/IMIfindpartners

Future Calls – topics in the pipeline

The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. Discussions on these topics are still in their early stages. For this reason, the topics may change considerably and they will probably not be ready for inclusion in an IMI Call for proposals for several months. Furthermore, as the discussions advance, it is likely that some topics will be added to this list while others will be dropped. In any case, we hope that this list will give potential applicants a useful glimpse into what is under development in the longer term, and provide additional time to enhance their network.
A pdf with summaries of the topic ideas can be found on the Future Topics page of the IMI website (bit.ly/FutureTopics). We will update this list whenever we have updates on the status of the topics.

<table>
<thead>
<tr>
<th>Subject area</th>
<th>Topic Ideas</th>
</tr>
</thead>
</table>
| Neurodegeneration and other neuroscience priorities | Digital transformation of clinical trial endpoints in pain  
Placebo effect in pain  
Psychiatric ratings using intermediate stratified markers - 2 |
| Immunology                                       | Psoriatic arthritis                                                                                                                         |
| Infection control including vaccines             | New topic(s) under the AMR accelerator platform                                                                                             |
| Translational safety                             | Dosing in specific populations  
Digital pathology                                                                                                                             |
| Big data, digital health, clinical trials and regulatory research | ROADMAP 2: need and opportunity for public-private collaborative research to continue the RoadMap efforts  
Independent observatories of health outcomes for patients being the guardians of health data  
E-product information. Leveraging digital technology to drive the correct use and understanding of medicines: a user-centric approach to adherence and risk minimisation |
| Oncology                                         | Patient-reported outcomes and quality of life endpoints                                                                                     |
| Facilitating the translation of advanced therapies to patients in Europe | Accelerating research and development of Advanced Therapies  
ATMP Patient Registries Outcomes Data and Evidence  
CAR-Ts  
Innovative Manufacturing of Advanced Therapeutic Medicinal Products, ATMPs                                                                 |
| Other enablers of research topics                | Handling of biologic drug products                                                                                                         |

**About the Innovative Medicines Initiative**

At IMI, we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

We do this by facilitating collaboration between the key players involved in healthcare research.

We are a partnership between the European Union and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), and have a €3.3 billion budget for the period 2014-2020.

Since our launch in 2008, we have launched over 100 projects in areas as diverse as dementia, pain, diabetes, autoimmune disease and antimicrobial resistance as well as tools for drug discovery and development, clinical trial design, and drug and vaccine safety.

**Stay in touch**

Visit the IMI website: [www.imi.europa.eu](http://www.imi.europa.eu)  
Follow us on Twitter: [@IMI_JU](https://twitter.com/IMI_JU)  
Join the IMI group on LinkedIn: [bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)  
E-mail us: [infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)  